Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021
-
Published:2023-07-04
Issue:
Volume:7
Page:101
-
ISSN:2572-4754
-
Container-title:Gates Open Research
-
language:en
-
Short-container-title:Gates Open Res
Author:
Munywoki Patrick K.ORCID, Bigogo Godfrey, Nasimiyu Carolyne, Ouma Alice, Aol George, Oduor Clifford O., Rono Samuel, Auko Joshua, Agogo George O., Njoroge Ruth, Oketch Dismas, Odhiambo Dennis, Odeyo Victor W., Kikwai Gilbert, Onyango Clayton, Juma Bonventure, Hunsperger ElizabethORCID, Lidechi Shirley, Ochieng Caroline Apondi, Lo Terrence Q., Munyua Peninah, Herman-Roloff Amy
Abstract
Background: SARS-CoV-2 has extensively spread in cities and rural communities, and studies are needed to quantify exposure in the population. We report seroprevalence of SARS-CoV-2 in two well-characterized populations in Kenya at two time points. These data inform the design and delivery of public health mitigation measures. Methods: Leveraging on existing population based infectious disease surveillance (PBIDS) in two demographically diverse settings, a rural site in western Kenya in Asembo, Siaya County, and an urban informal settlement in Kibera, Nairobi County, we set up a longitudinal cohort of randomly selected households with serial sampling of all consenting household members in March and June 2021. Both sites included 1,794 and 1,638 participants in March and June 2021, respectively. Individual seroprevalence of SARS-CoV-2 antibodies was expressed as a percentage of the seropositive among the individuals tested, accounting for household clustering and weighted by the PBIDS age and sex distribution. Results: Overall weighted individual seroprevalence increased from 56.2% (95%CI: 52.1, 60.2%) in March 2021 to 63.9% (95%CI: 59.5, 68.0%) in June 2021 in Kibera. For Asembo, the seroprevalence almost doubled from 26.0% (95%CI: 22.4, 30.0%) in March 2021 to 48.7% (95%CI: 44.3, 53.2%) in July 2021. Seroprevalence was highly heterogeneous by age and geography in these populations—higher seroprevalence was observed in the urban informal settlement (compared to the rural setting), and children aged <10 years had the lowest seroprevalence in both sites. Only 1.2% and 1.6% of the study participants reported receipt of at least one dose of the COVID-19 vaccine by the second round of serosurvey—none by the first round. Conclusions: In these two populations, SARS-CoV-2 seroprevalence increased rapidly in the first 16 months of the COVID-19 pandemic in Kenya. It is important to prioritize additional mitigation measures, such as vaccine distribution, in crowded and low socioeconomic settings.
Funder
Centers for Disease Control and Prevention Bill and Melinda Gates Foundation
Publisher
F1000 Research Ltd
Subject
Public Health, Environmental and Occupational Health,Health Policy,Immunology and Microbiology (miscellaneous),Biochemistry, Genetics and Molecular Biology (miscellaneous),Medicine (miscellaneous)
Reference37 articles.
1. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China.;R Huang;Lancet Infect Dis.,2020 2. Coronavirus disease 2019 (COVID-19): situation report, 73.,2022 3. An interactive web-based dashboard to track COVID-19 in real time.;E Dong;Lancet Infect Dis.,2020 4. Update on COVID-19 in the country and response measures as at December 31, 2021. 5. Disease Control Priorities in Developing Countries.;D Jamison;Public Health Surveillance: A Tool for Targeting and Monitoring Interventions.,2006
|
|